ASML to 2035 still has a rare long-term strategic franchise, but the long-range stock outlook should be framed with explicit revenue, margin, and valuation assumptions rather than pure enthusiasm.

ASML to 2030 still has one of the clearest strategic runways in European technology, but long-term targets should be anchored in official demand and margin signals rather than pure AI enthusiasm.

Eli Lilly still has a credible path to a materially larger business by 2030, but the stock is no longer cheap enough for optimism alone. The central question is whether obesity, diabetes, and pipeline ...

DAX 40 outlook with quantified scenarios, earnings and valuation context, macro triggers, and institutional views for 2027.

How AI could affect platinum prices through electricity demand, industrial demand, and long-term capital spending.

The decade thesis is that DAX remains Europe's premier industrial and software beta. A decade from now, the most important question is whether Germany emer ...

AstraZeneca can still rally from $184.96, but the bullish case now depends on execution rather than a rerating story. The clean version of that case is straightforward: guidance holds, launches ...

Microsoft stock analysis with current valuation, earnings, AI exposure, macro context, and scenario-based ranges backed by current sources.

A data-grounded bearish case for the AEX Index with current inflation, growth, valuation, concentration risk, and measurable downside scenarios.

S&P 500 with valuation, earnings, inflation, scenario probabilities, trigger levels, and institutional data updated for mid-2026.

Why Sensex could keep rising, with measurable catalysts, valuation context, institutional views, and scenario-based positioning.

Why Sensex could fall further, with measurable risks, valuation context, institutional views, and scenario-based positioning.